Comparison of Outcomes and Complications of Phaco-Trabeculectomy (PT) With Phaco-Viscocanalostomy (PVC) in glaucoma patients

Not Applicable

Recruiting

• Conditions: Condition 1: Glaucoma is a group of disorders that differ in their pathophysiology, risk factors, manifestations, treatments, and prognoses. Their common feature is progressive degeneration of the optic nerve, with loss of retinal ganglion cells, thinning of the retinal nerve fiber layer, and progressive excavation of the optic disc. Condition 2: A cataract is a cloudy area in the lens of the eye that leads to a decrease in vision. It often develop slowly and can affect one or both eyes.; Absolute glaucoma; Unspecified cataract; H44.51; H26.9

• Registration Number: IRCT20220116053736N1
• Lead Sponsor: Kerman University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Glaucoma of Primary Open-Angle Glaucoma (POAG), Pseudoexfoliative Glaucoma (PXG), Chronic Angle Closure Glaucoma (CACG) uncontrolled with at least 2 topical medications (0.5% thymolol drops, 2 times a day) and dorsolamide 3 times daily (IOP > 21 mm Hg).
Glaucoma of Primary Open-Angle Glaucoma (POAG), Pseudoexfoliative Glaucoma (PXG), Chronic Angle Closure Glaucoma (CACG) Despite using several anti-glaucoma drugs.
Significant cataract (BCVA =20 / 60) justified by lens opacity.

Exclusion Criteria

History of intraocular surgery such as vitreous and retinal surgery
Phacomorphic glaucoma
Significant corneal opacity
Secondary glaucoma (Uveitis Glaucoma, neovascular glaucoma, pigmentary glaucoma)
Diabetic retinopathy
History of eye trauma
Posterior chamber eye diseases
History of phycoemulsification (PE) and glaucoma surgeries
Incomplete participants' information (> 10%)
Signing the written informed consent

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Intraocular pressure (IOP). Timepoint: At the beginning of the study (before the intervention), in the first and fourth weeks, and sixth months after surgery. Method of measurement: Goldmann tonometry.;Number of drops used to reduce IOP. Timepoint: Before intervention, 1 and 4 weeks and 6 months after intervention. Method of measurement: The designed checklist.;Intraoperative complications. Timepoint: From the beginning to the end of the surgery. Method of measurement: Examination by a glaucoma subspecialist.;Postoperative early complications. Timepoint: In 1 and 4 weeks following surgery. Method of measurement: Examination by a glaucoma subspecialist.;Postoperative late complications. Timepoint: Six months after surgery. Method of measurement: Examination by a glaucoma subspecialist.;Visual Acuity. Timepoint: Before intervention, 1 and 4 weeks and 6 months after surgery. Method of measurement: Snellen chart.

Secondary Outcome Measures

Name	Time	Method
eed to use antiglaucoma drugs after surgery. Timepoint: In the first and fourth weeks and the sixth month after surgery. Method of measurement: Examination by a glaucoma subspecialist.